| |
[摘要]：Brivaracetam is a racetam derivative with anticonvulsant properties. It binds to synoptic vesicle glycoprotein 2A (SV2A) to produce its clinical effect. Brivaracetam is believed to have brood antiseizure activity, a relatively benign adverse event profile and good tolerability Brivaracetam undergoes complete absorption after oral administration, with time to peak plasma concentrations of 0.5-1.75 h. It has been reported to interact with and moderately decrease the levels of carbamazepine, phenytoin and oral contraceptives. Recent phase Ill trials with this molecule have yielded contrasting results and future studies looking at this potential broad-spectrum anticonvulsant will determine its place in the clinician's armamentarium. |
|
